Figure 6.

hAAT Gene Therapy Extends the Lifespan of NZM2410 Mice

8-week-old female NZM2410 mice were injected with PBS (n = 10) as a control, hAAT (n = 7, 2 mg/mouse, every 3 days), and rAAV8-CB-hAAT (n = 10, 1 × 10¹¹ particles/mouse). The experiment was terminated at 72 weeks of age. (A) Serum hAAT levels in the hAAT-treated group. (B) Serum hAAT levels in the rAAV8-CB-hAAT-treated group. (C) Anti-hAATIgG levels. (D) Relative murine AAT levels (relative unit to C57BL/6 levels) in PBS-, hAAT-, and rAAV8-CB-hAAT-treated NZM2410 mice. (E) Kaplan-Meier curves showing survival of mice treated with PBS alone or hAAT or rAAV8-CB-hAAT. Data were expressed as the mean ± SEM. p (PBS versus hAAT) = 0.0547 and **p (PBS versus rAAV8-CB-hAAT) < 0.01.